Aminologics Co.Ltd (074430) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Aminologics Co.Ltd stock KRW 1,112, price KRW 970, upside +14.6%, quality 69 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 863.00 KRW – 3,485 KRW · fair‑value band 920.96 KRW – 1,388 KRW · the 970.00 KRW price screens below the 1,112 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Aminologics Co.Ltd in your weekly email
Every Wednesday you see whether Aminologics Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea.
Show moreShow less
Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D-leucine, D-valine, 4-chloro-L-phenylalanine, D-histidine, Fmoc-D-allo-isoleucine, Fmoc-D-alanine, and Fmoc-D-phenylalanine.
The company's products also comprise Boc-D-phenylalanine, L-homophenylalanine, D-homophenylalanine, 3-(3-pyridyl)-L-alanine, 3-(3-pyridyl)-D-alanine, D-cysteine HCL H2O, D-serine methyl ester HCl, Boc-D-Ser-OH, D-threonine, Fmoc-D-Leu-OH, Boc-D-4-Benzoylphenylalanine, Fmoc-D-Cyclohexylalanine, Fmoc-D-Pentafluorophenylalanine, Fmoc-D-Trp(Boc)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-D-Ser(tBu)-OH, and Fmoc-L-Ser(tBu)-OH. In addition, it operates resort and power generation businesses.
Aminologics Co.,Ltd. was founded in 1997 and is headquartered in Seoul, South Korea.
Stock analysis
Aminologics Co.Ltd (074430) currently trades at 970.00 KRW, while our model-based Fair Value estimate is 1,112 KRW, implying the stock looks roughly 13% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 684.40 KRW per share, and 1 of the 24 models we run sit above the 970.00 KRW price.
Bear case: the Earnings-Based group reads lowest at 419.33 KRW, and 23 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 920.96 KRW (bear) to 1,388 KRW (bull), the price of 970.00 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Aminologics Co.Ltd reported revenue of 22.0B KRW in FY2025 versus 22.8B KRW in FY2021, a compound −0.9%/yr. Reported net income was 3.5B KRW in FY2025, compounding −10.0%/yr from FY2021.
Key figures
Market cap 85.2B KRW (≈ $63.0M) Micro · P/S ratio 3.15 · Net margin 20.6% · Return on equity −105% · Return on assets (EBIT) −1.3% (5-year average) · Operating margin 26.0% · Revenue (TTM) 27.9B KRW · Revenue growth (YoY) +73.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at 15%, 074430 screens cheaper than that median.
Fair Value models
Bear920.96 KRWFair Value 1,112 KRWBull1,388 KRW
Price 970.00 KRW · Upside +14.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+31.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.2%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 16%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +21.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+14.6% · Above median
Profitability
Return on assets4.2% · Above median
Net margin (12 months)20.6% · Top 25%
Operating margin (12 months)26.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)73.0% · Top 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Aminologics Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/074430
Frequently asked questions
Is Aminologics Co.Ltd (074430) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 1,112 KRW versus a price of 970.00 KRW, about +15% upside (undervalued).
What is the fair value of 074430?
Our model-based fair value for Aminologics Co.Ltd is 1,112 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 970.00 KRW.
What is the quality score of 074430?
Aminologics Co.Ltd has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aminologics Co.Ltd (074430)?
Our model-based price target is the fair value of 1,112 KRW (as of Nov 5, 2026) from 24 valuation models. Cautious scenario 920.96 KRW, optimistic scenario 1,388 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Aminologics Co.Ltd stock forecast for 2026?
Our models put fair value at 1,112 KRW, about +15% upside versus a price of 970.00 KRW (undervalued). Cautious scenario 920.96 KRW, optimistic scenario 1,388 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Aminologics Co.Ltd (074430)?
Aminologics Co.Ltd reported trailing-twelve-month revenue of about 27.9B KRW (latest available figure, as of Nov 5, 2026).
What growth is priced into Aminologics Co.Ltd (074430)?
For today's price to be fair in a discounted-cash-flow model, Aminologics Co.Ltd would have to grow free cash flow by +23.9 % per year for five years (discount rate 13.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.5 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 074430 use?
Our models discount Aminologics Co.Ltd at 13.6 %: a base by market capitalisation (micro), damped by beta 1.14, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Aminologics Co.Ltd that is +23.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.6 %) and the same formula as our fair value.
How much growth has Aminologics Co.Ltd (074430) delivered so far?
Over the past 5 years revenue at Aminologics Co.Ltd grew +4.5 % a year. The price currently implies free-cash-flow growth of +23.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Aminologics Co.Ltd (074430) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Aminologics Co.Ltd (+23.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Aminologics Co.Ltd (074430)?
The free-cash-flow yield on the price is 2.93 %: that much free cash flow Aminologics Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Aminologics Co.Ltd (074430)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aminologics Co.Ltd it is 1,112 KRW per share (as of Nov 5, 2026), against a price of 970.00 KRW. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Aminologics Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 074430 trades below its calculated fair value: price 970.00 KRW, fair value 1,112 KRW, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 074430?
No. The price is what the market pays today (970.00 KRW); the fair value is what the company's own numbers justify (1,112 KRW). For Aminologics Co.Ltd the two are 142.10 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aminologics Co.Ltd worth?
The market values Aminologics Co.Ltd at about 85.2B KRW (market capitalisation, as of Nov 5, 2026). Per share that is 970.00 KRW; our models calculate a fair value of 1,112 KRW per share.
What do the bullish and bearish scenarios say about 074430?
Our models span a range for Aminologics Co.Ltd: cautious scenario 920.96 KRW, base 1,112 KRW, optimistic 1,388 KRW per share (as of Nov 5, 2026, price 970.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aminologics Co.Ltd (074430)?
Balance-sheet figures for Aminologics Co.Ltd (as of Nov 5, 2026): return on equity −105.5%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 074430 from its 52-week high?
Aminologics Co.Ltd trades at 970.00 KRW, about 47% below its 52-week high of 1,838 KRW and 12% above the low of 863.00 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,112 KRW is for.
Which stocks are comparable to Aminologics Co.Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aminologics Co.Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 970.00 KRW, calculated fair value 1,112 KRW (+15%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 074430 calculated?
We run Aminologics Co.Ltd through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,112 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Aminologics Co.Ltd currently trades 13% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aminologics Co.Ltd (074430)?
The closing price on Nov 6, 2026 was 970.00 KRW. Our model-based fair value is 1,112 KRW, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aminologics Co.Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Aminologics Co.Ltd
How large is the market capitalisation of Aminologics Co.Ltd (074430)?
The market capitalisation of Aminologics Co.Ltd is 85.2B KRW (≈ $63.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aminologics Co.Ltd (074430)?
The price-to-sales ratio of Aminologics Co.Ltd is 3.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Aminologics Co.Ltd (074430)?
The net margin of Aminologics Co.Ltd is 20.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aminologics Co.Ltd (074430)?
The return on equity (ROE) of Aminologics Co.Ltd is −105% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aminologics Co.Ltd (074430)?
On an EBIT basis the return on assets of Aminologics Co.Ltd is −1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aminologics Co.Ltd (074430)?
The operating margin of Aminologics Co.Ltd is 26.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aminologics Co.Ltd (074430)?
Revenue at Aminologics Co.Ltd is growing +73.0% versus a year earlier (3y avg −7.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aminologics Co.Ltd (074430)?
Earnings per share at Aminologics Co.Ltd are growing +168% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Aminologics Co.Ltd in the live analysis
One click puts Aminologics Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026